Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARTV Artiva Biotherapeutics	$2.88 +4.0%	$2.32	$1.47 ▼ $17.31	$70.35M	N/A	224,301 shs	50,086 shs
BYSI BeyondSpring	$1.76	$2.25	$0.98 ▼ $3.44	$70.98M	0.26	36,319 shs	26,529 shs
PIRS Pieris Pharmaceuticals	$13.60	$15.17	$12.63 ▼ $18.68	$17.95M	0.61	90,136 shs	51,728 shs
VNRX VolitionRx	$0.69 +1.0%	$0.71	$0.40 ▼ $0.94	$74.03M	1.26	196,231 shs	151,691 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARTV Artiva Biotherapeutics	+2.21%	+2.59%	+7.36%	+42.05%	-72.49%
BYSI BeyondSpring	+2.33%	-12.44%	-5.88%	+1.79%	-6.88%
PIRS Pieris Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	-25.07%
VNRX VolitionRx	+3.15%	+5.78%	-7.87%	+32.10%	+0.15%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARTV Artiva Biotherapeutics	2.8392 of 5 stars	3.5	0.0	0.0	0.0	1.6	2.5	1.3
BYSI BeyondSpring	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PIRS Pieris Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VNRX VolitionRx	2.206 of 5 stars	3.5	0.0	0.0	0.0	2.1	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARTV Artiva Biotherapeutics	3.00	Buy	$17.00	490.28% Upside
BYSI BeyondSpring	0.00	N/A	N/A	N/A
PIRS Pieris Pharmaceuticals	0.00	N/A	N/A	N/A
VNRX VolitionRx	3.00	Buy	$3.50	408.72% Upside

Current Analyst Ratings Breakdown

Latest PIRS, BYSI, VNRX, and ARTV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	VNRX VolitionRx	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
7/17/2025	VNRX VolitionRx	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
7/9/2025	VNRX VolitionRx	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
6/11/2025	ARTV Artiva Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$12.00
6/10/2025	VNRX VolitionRx	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$3.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARTV Artiva Biotherapeutics	N/A	N/A	N/A	N/A	$6.10 per share	N/A
BYSI BeyondSpring	N/A	N/A	N/A	N/A	($0.44) per share	N/A
PIRS Pieris Pharmaceuticals	$42.81M	0.42	N/A	N/A	$21.66 per share	0.63
VNRX VolitionRx	$1.32M	56.11	N/A	N/A	($0.11) per share	-6.25

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARTV Artiva Biotherapeutics	-$65.37M	N/A	0.00	N/A	N/A	N/A	-42.60%	-37.76%	N/A
BYSI BeyondSpring	-$11.12M	N/A	0.00	∞	N/A	N/A	N/A	N/A	11/6/2025 (Estimated)
PIRS Pieris Pharmaceuticals	-$24.54M	-$12.10	N/A	∞	N/A	-39.71%	-80.93%	-59.55%	N/A
VNRX VolitionRx	-$35.32M	-$0.25	N/A	∞	N/A	-2,321.14%	N/A	-163.39%	N/A

Latest PIRS, BYSI, VNRX, and ARTV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2025	Q2 2025	BYSI BeyondSpring	N/A	-$0.04	N/A	-$0.04	N/A	N/A
8/6/2025	Q2 2025	ARTV Artiva Biotherapeutics	-$0.84	-$0.87	-$0.03	-$0.87	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARTV Artiva Biotherapeutics	N/A	N/A	N/A	N/A	N/A
BYSI BeyondSpring	N/A	N/A	N/A	N/A	N/A
PIRS Pieris Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VNRX VolitionRx	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARTV Artiva Biotherapeutics	N/A	13.84	13.84
BYSI BeyondSpring	N/A	2.19	2.19
PIRS Pieris Pharmaceuticals	N/A	4.82	4.82
VNRX VolitionRx	N/A	0.22	0.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARTV Artiva Biotherapeutics	N/A
BYSI BeyondSpring	40.29%
PIRS Pieris Pharmaceuticals	40.11%
VNRX VolitionRx	8.09%

Insider Ownership

Company	Insider Ownership
ARTV Artiva Biotherapeutics	21.40%
BYSI BeyondSpring	29.31%
PIRS Pieris Pharmaceuticals	6.39%
VNRX VolitionRx	10.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARTV Artiva Biotherapeutics	81	24.43 million	19.20 million	N/A
BYSI BeyondSpring	80	40.33 million	28.51 million	Optionable
PIRS Pieris Pharmaceuticals	140	1.32 million	1.24 million	Optionable
VNRX VolitionRx	80	107.60 million	80.80 million	Optionable

PIRS, BYSI, VNRX, and ARTV Headlines

Recent News About These Companies

Q3 Earnings Forecast for VolitionRx Issued By HC Wainwright

August 22 at 7:20 AM | marketbeat.com

Research Analysts Issue Forecasts for VolitionRx Q3 Earnings

August 22 at 2:29 AM | americanbankingnews.com

HC Wainwright Has Negative Outlook of VolitionRx Q4 Earnings

August 21 at 6:53 AM | marketbeat.com

Equities Analysts Issue Forecasts for VolitionRx Q4 Earnings

August 21 at 2:23 AM | americanbankingnews.com

D. Boral Capital Reiterates "Buy" Rating for VolitionRx (NYSE:VNRX)

August 17, 2025 | marketbeat.com

VolitionRx Limited (AMEX:VNRX) Q2 2025 Earnings Call Transcript

August 16, 2025 | msn.com

VolitionRx Limited (VNRX) Q2 2025 Earnings Call Transcript

August 15, 2025 | seekingalpha.com

VolitionRx reports Q2 revenue $400K, consensus $375.72K

August 14, 2025 | msn.com

VolitionRx Limited Announces Second Quarter 2025 Financial Results and Business Update

August 14, 2025 | prnewswire.com

Insights into VolitionRX's Upcoming Earnings

August 14, 2025 | benzinga.com

VolitionRx (NYSE:VNRX) Stock Price Down 4.3% - Here's What Happened

August 9, 2025 | marketbeat.com

VolitionRx Limited Schedules Second Quarter 2025 Earnings Conference Call and Business Update | ...

August 8, 2025 | gurufocus.com

VolitionRx Limited Schedules Second Quarter 2025 Earnings Conference Call and Business Update

August 8, 2025 | prnewswire.com

Insider Buying: VolitionRx Limited (NYSE:VNRX) Director Buys 78,125 Shares of Stock

August 7, 2025 | marketbeat.com

Cameron John Reynolds Buys 78,125 Shares of VolitionRx Limited (NYSE:VNRX) Stock

August 7, 2025 | marketbeat.com

VolitionRx Limited (NYSE:VNRX) Director Acquires $50,000.00 in Stock

August 7, 2025 | insidertrades.com

VolitionRx Announces Pricing of $1.2 Million Registered Direct Offering

August 4, 2025 | prnewswire.com

Nu.Q® Discover Expands Global Adoption and Epigenetic Innovation

July 16, 2025 | prnewswire.com

VolitionRx Limited (VNRX) - Yahoo Finance

July 11, 2025 | nz.finance.yahoo.com

Volition Announces Groundbreaking Lateral Flow Test for Point-of-Care Quantification of Nucleosomes

July 8, 2025 | prnewswire.com

Volition Announces MARS Consortium Clinical Study Suggests Nu.Q® H3.1. Concentrations are Closely Associated with Sepsis and Organ Failure

June 12, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PIRS, BYSI, VNRX, and ARTV Company Descriptions

Artiva Biotherapeutics NASDAQ:ARTV

$2.88 +0.11 (+3.97%)

Closing price 04:00 PM Eastern

Extended Trading

$2.88 +0.00 (+0.17%)

As of 05:23 PM Eastern

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

BeyondSpring NASDAQ:BYSI

$1.76 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$1.76 +0.00 (+0.28%)

As of 04:10 PM Eastern

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

Pieris Pharmaceuticals NASDAQ:PIRS

Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.

VolitionRx NYSE:VNRX

$0.68 +0.00 (+0.29%)

As of 04:00 PM Eastern

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time